Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serigne Lo

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
The Medical Journal of Australia|April 26, 2021
An electronic decision support-based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE)Ruth Webster, Tim Usherwood, Rohina Joshi, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sitesJordan W Conway, Robert V Rawson, Serigne Lo, et al.
Annals of Surgical Oncology|June 1, 2018
1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility StudyMarc D Moncrieff, David Gyorki, Robyn Saw, et al.
Annals of Surgical Oncology|June 28, 2018
Correction to: 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility StudyMarc D Moncrieff, David Gyorki, Robyn Saw, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 13, 2021
Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trialAmelia K Smit, Martin Allen, Brooke Beswick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 TherapyHansol Lee, Angela L Ferguson, Camelia Quek, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
Nature Communications|February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Nature Communications|May 17, 2022
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
The Medical Journal of Australia|April 26, 2021
An electronic decision support-based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE)Ruth Webster, Tim Usherwood, Rohina Joshi, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sitesJordan W Conway, Robert V Rawson, Serigne Lo, et al.
Annals of Surgical Oncology|June 1, 2018
1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility StudyMarc D Moncrieff, David Gyorki, Robyn Saw, et al.
Annals of Surgical Oncology|June 28, 2018
Correction to: 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility StudyMarc D Moncrieff, David Gyorki, Robyn Saw, et al.
The Lancet. Oncology|June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trialGeorgina V Long, Robyn P M Saw, Serigne Lo, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 13, 2021
Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trialAmelia K Smit, Martin Allen, Brooke Beswick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2023
Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 TherapyHansol Lee, Angela L Ferguson, Camelia Quek, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.
Nature Communications|February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Nature Communications|May 17, 2022
Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomesManik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Pageof 11